Business Context and Reporting Period
Company: MetLife, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: MetLife is a leading global financial services company providing insurance, annuities, employee benefits, and asset management. Operations are organized into six segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Total Revenues | $17,823 | $16,623 | $33,880 | $32,011 |
| Net Income (GAAP) | $953 | $408 | $1,828 | $493 |
| Net Income Available to Common Shareholders | $912 | $370 | $1,712 | $384 |
| Adjusted Earnings | $1,662 | $1,524 | $3,063 | $2,774 |
| Adjusted Earnings Available to Common Shareholders | $1,628 | $1,492 | $2,962 | $2,676 |
| Diluted EPS (GAAP) | $1.28 | $0.48 | $2.37 | $0.50 |
| Net Investment Income | $5,205 | $5,072 | $10,641 | $9,717 |
| Net Investment Gains (Losses) | ($421) | ($1,039) | ($796) | ($1,723) |
| Net Derivative Gains (Losses) | ($508) | ($997) | ($1,487) | ($1,087) |
| Total Assets | $675,745 | $687,584 | $675,745 | $687,584 |
| Total Liabilities | $648,205 | $657,331 | $648,205 | $657,331 |
| Stockholders' Equity | $27,252 | $30,015 | $27,252 | $30,015 |
| Cash and Cash Equivalents | $20,786 | $20,639 | $20,786 | $20,639 |
| Long-term Debt | $14,809 | $15,548 | $14,809 | $15,548 |
Material Changes vs. Prior Period
- Net Income Growth: Net income available to common shareholders increased significantly to $912 million in Q2 2024 from $370 million in Q2 2023. This was driven primarily by a favorable change in net investment gains (losses) and net derivative gains (losses), partially offset by an unfavorable change in market risk benefit (MRB) remeasurement and a higher effective tax rate.
- Investment Performance: Net investment gains (losses) improved to a loss of $421 million in Q2 2024 compared to $1,039 million in Q2 2023, largely due to the absence of impairment losses in the current period that were present in the prior period related to a reinsurance transaction.
- Derivative Volatility: Net derivative losses narrowed to $508 million in Q2 2024 from $997 million in Q2 2023, attributed to less significant increases in key equity indexes and long-term interest rates compared to the prior period.
- Market Risk Benefits: MRB remeasurement losses were $182 million in Q2 2024 compared to $817 million in Q2 2023. The filing notes that while the loss was smaller, it was still an unfavorable change relative to the prior period's specific market dynamics.
- Segment Performance: Adjusted earnings increased across most segments. Group Benefits saw a $161 million increase driven by favorable mortality and morbidity results. Asia and Latin America also reported growth, while MetLife Holdings declined due to expected business run-off and a reinsurance transaction.
Guidance, Outlook, and Risks
- Outlook: Management continues to monitor global financial and economic conditions, including inflation, supply chain disruptions, and banking sector volatility. The company expects continued impact from rising market interest rates on its investment portfolio and derivatives.
- Capital Actions: MetLife repurchased approximately 12 million shares of common stock in Q2 2024. As of June 30, 2024, approximately $3.1 billion remained under common stock repurchase authorizations. Dividends on common stock were declared at $0.545 per share for the quarter.
- Key Risks:
- Market Risk: Exposure to interest rate, foreign currency exchange rate, credit, and equity market risks. Changes in these factors significantly impact net investment gains/losses and derivative valuations.
- Investment Credit Risk: Gross unrealized losses on fixed maturity securities available-for-sale (AFS) increased to $30.4 billion, primarily due to rising interest rates. Management does not intend to sell these securities before recovery.
- Regulatory Environment: Ongoing monitoring of regulatory developments regarding AI in underwriting, climate-related disclosures, and fiduciary definitions under ERISA.
- Legal Proceedings: Significant exposure to asbestos-related claims and litigation regarding unclaimed property reports. Management believes adequate provisions have been made, but outcomes remain uncertain.
Investor Verification Checklist
- Investment Portfolio Quality: Verify the composition of the $30.4 billion in gross unrealized losses on fixed maturity securities AFS and management's assessment of credit loss allowances (ACL).
- Derivative Hedging Effectiveness: Review the impact of non-qualifying derivatives on earnings volatility, specifically the $1.5 billion net derivative loss for the six months ended June 30, 2024.
- Reinsurance Transaction Impact: Assess the long-term impact of the November 2023 reinsurance transaction on the MetLife Holdings segment's adjusted earnings.
- Foreign Currency Exposure: Monitor the impact of the weakening Japanese yen and other foreign currencies on the Asia and Latin America segments' reported earnings.
- Asbestos Liability: Review the rollforward of asbestos-related claims and the adequacy of the recorded liability given the uncertainty of future claims.
- Capital Return Policy: Confirm the sustainability of the current dividend rate and share repurchase program given the company's liquidity position and regulatory constraints on subsidiary dividends.